|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Buzdar AU, on behalf of the ATAC Trialists’ Group. Clinical features of joint symptoms observed in the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. Proc ASCO 2006;Abstract 551.
Coleman RE, on behalf of the ATAC Trialists’ Group. Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. Proc ASCO 2006;Abstract 511.
Coombes RC et al. First mature analysis of the Intergroup Exemestane Study. Proc ASCO 2006;Abstract LBA 527.
Doyle JJ et al. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 2005;23(34):8597-605. Abstract
Giordano SH et al. Congestive heart failure (CHF) in older women treated with anthracycline (A) chemotherapy (C). Proc ASCO 2006;Abstract 521.
Goss PE et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. San Antonio Breast Cancer Symposium 2005;Abstract 16.
Hayes DF et al. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. Proc ASCO 2006;Abstract 510.
Howell A, on behalf of the ATAC Trialists’ Group. Analysis of fracture risk factors from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: 5-year data. Proc ASCO 2006;Abstract 563.
Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract
Ingle J et al. NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. Proc ASCO 2006;Abstract 549.
Jones LW et al. Cardiovascular risk profile of breast cancer patients treated with anthracycline- taxane containing adjuvant chemotherapy and/or trastuzumab. Proc ASCO 2006;Abstract 666.
Jones SE et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 40.
Jones SE et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23(24):5542-51. Abstract
Kaufmann M et al. Survival benefit of switching to anastrozole after 2 years’ treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study. Proc ASCO 2006;Abstract 547.
Lin NU et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. Proc ASCO 2006;Abstract 503.
Lonning, PE et al. Changes in bone metabolism after 2 years’ treatment with exemestane (E) in postmenopausal women with early breast cancer (EBC) at low risk: Follow-up (FU) results of a randomized placebo-controlled study. Proc ASCO 2005;Abstract 531.
Mamounas EP et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 2005;23(16):3686-96. Abstract
Muss HB et al; Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293(9):1073-81. Abstract
Perez EA et al. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. Proc ASCO 2006;Abstract 583.
Robert NJ et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. Proc ASCO 2006;Abstract 550.
Shepherd LE et al. Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience. Proc ASCO 2006;Abstract 522.
Sparano JA et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: Results of North American Breast Cancer Intergroup Trial E1199. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 48.
Spector NL et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. Proc ASCO 2006;Abstract 502.
 |
 |
